Regeneron Pharmaceuticals Inc. buy Rothschild & Co Redburn
Start price
14.08.25
/
50%
€481.00
Target price
14.08.26
€759.88
Performance (%)
26.02%
Price
08.12.25
€604.40
Summary
This prediction is currently active. The prediction currently has a performance of 26.02%. A total of €1.76 was paid as dividends for this prediction. This prediction currently runs until 14.08.26. The prediction end date can be changed by Rothschild___Co_Redb at any time. Rothschild___Co_Redb has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -6.440% | -6.440% |
| iShares Core DAX® | 1.917% | 1.088% |
| iShares Nasdaq 100 | 0.911% | 1.674% |
| iShares Nikkei 225® | 0.833% | -1.712% |
| iShares S&P 500 | 0.242% | 1.258% |
Comments by Rothschild___Co_Redb for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $890.00 price target on the stock.
Ratings data for REGN provided by MarketBeat